Mechanisms and insights into drug resistance in cancer

Frontiers in Pharmacology

Volumn 4 MAR, Issue , 2013, Pages

  Zahreddine, Hiba ^a   Borden, Katherine L B ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Collateral sensitivity; Drug metabolism; Drug transporters; Microenvironment; Multidrug resistance; Oncogene addiction; Origin of cancer; Synthetic lethality

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; BORTEZOMIB; CISPLATIN; CYCLOPAMINE; CYTARABINE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; IMATINIB; INIPARIB; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NATALIZUMAB; OXALIPLATIN; PACLITAXEL; RETINOIC ACID; TRASTUZUMAB; UNINDEXED DRUG; VELIPARIB; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOCARCINOMA; APOPTOSIS; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL SUBPOPULATION; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NONHUMAN; OVARY CARCINOMA; PROSTATE CARCINOMA; SHORT SURVEY;

EID: 84878102548     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00028     Document Type: Short Survey

References (149)

1. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., et al. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2, 811-814.
2. Apperley, J. F. (2007). Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8, 1018-1029.
3. Arber, N., Doki, Y., Han, E. K., Sgambato, A., Zhou, P., Kim, N. H., et al. (1997). Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 57, 1569-1574.
4. Atwood, S. X., Chang, A. L., and Oro, A. E. (2012). Hedgehog pathway inhibition and the race against tumor evolution. J. Cell Biol. 199, 193-197.
5. Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12, 6494-6501.
6. Bardenheuer, W., Lehmberg, K., Rattmann, I., Brueckner, A., Schneider, A., Sorg, U. R., et al. (2005). Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 19, 2281-2288.
7. Bean, J., Riely, G. J., Balak, M., Marks, J. L., Ladanyi, M., Miller, V. A., et al. (2008). Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res. 14, 7519-7525.
8. Bidard, F. C., Vincent-Salomon, A., Gomme, S., Nos, C., De Rycke, Y., Thiery, J. P., et al. (2008). Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin. Cancer Res. 14, 3306-3311.
9. Blencke, S., Ullrich, A., and Daub, H. (2003). Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278, 15435-15440.
10. Borsellino, N., Belldegrun, A., and Bonavida, B. (1995). Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 55, 4633-4639.
11. Borsellino, N., Bonavida, B., Ciliberto, G., Toniatti, C., Travali, S., and D'Alessandro, N. (1999). Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85, 134-144.
12. Borst, P., Evers, R., Kool, M., and Wijnholds, J. (2000). A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92, 1295-1302.
13. Braun, S., Kentenich, C., Janni, W., Hepp, F., De Waal, J., Willgeroth, F., et al. (2000). Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18, 80-86.
14. Breivik, J. (2005). The evolutionary origin of genetic instability in cancer development. Semin. Cancer Biol. 15, 51-60.
15. Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917.
16. Cai, J., Weiss, M. L., and Rao, M. S. (2004). In search of "stemness". Exp. Hematol. 32, 585-598.
17. Campbell, P. J., Stephens, P. J., Pleasance, E. D., O'Meara, S., Li, H., Santarius, T., et al. (2008). Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 40, 722-729.
18. Castells, M., Thibault, B., Delord, J. P., and Couderc, B. (2012). Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int. J. Mol. Sci. 13, 9545-9571.
19. Caulin, A. F., and Maley, C. C. (2011). Peto's Paradox: evolution's prescription for cancer prevention. Trends Ecol. Evol. 26, 175-182.
20. Chiarugi, A. (2012). A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol. Sci. 33, 42-48.
21. Chin, L., and Gray, J. W. (2008). Translating insights from the cancer genome into clinical practice. Nature 452, 553-563.
22. Costa, D. B., Halmos, B., Kumar, A., Schumer, S. T., Huberman, M. S., Boggon, T. J., et al. (2007). BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4:e315. doi: 10.1371/journal.pmed.0040315
23. Crespi, B., and Summers, K. (2005). Evolutionary biology of cancer. Trends Ecol. Evol. 20, 545-552.
24. Croix, B. S., Rak, J. W., Kapitain, S., Sheehan, C., Graham, C. H., and Kerbel, R. S. (1996). Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88, 1285-1296.
25. Damaraju, V. L., Damaraju, S., Young, J. D., Baldwin, S. A., Mackey, J., Sawyer, M. B., et al. (2003). Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22, 7524-7536.
26. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
27. Engelhardt, B., and Kappos, L. (2008). Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener. Dis. 5, 16-22.
28. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
29. Farmer, H., Mccabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
30. Ferrantini, M., Capone, I., and Belardelli, F. (2007). Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89, 884-893.
31. Frassanito, M. A., Cusmai, A., Iodice, G., and Dammacco, F. (2001). Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97, 483-489.
32. Frei, E. III, Karon, M., Levin, R. H., Freireich, E. J., Taylor, R. J., Hananian, J., et al. (1965). The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26, 642-656.
33. Galmarini, C. M., Mackey, J. R., and Dumontet, C. (2001). Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15, 875-890.
34. Gatti, L., and Zunino, F. (2005). Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 111, 127-148.
35. Gioeli, D. (2011). Targeted Therapies Mechanisms of Resistance. New York: Humana Press.
36. Giona, F., Testi, A. M., Annino, L., Amadori, S., Arcese, W., Camera, A., et al. (1994). Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologia ed Ocologia Pediatrica. Br. J. Haematol. 86, 55-61.
37. Goldman, J. M., and Melo, J. V. (2003). Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451-1464.
38. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
39. Gottesman, M. M. (2002). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627.
40. Gottesman, M. M., Fojo, T., and Bates, S. E. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58.
41. Greaves, M. (2007). Darwinian medicine: a case for cancer. Nat. Rev. Cancer 7, 213-221.
42. Guha, M. (2011). PARP inhibitors stumble in breast cancer. Nat. Biotechnol. 29, 373-374.
43. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J. L., Maloisel, F., et al. (1997). Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N. Engl. J. Med. 337, 223-229.
44. Hall, M. D., Handley, M. D., and Gottesman, M. M. (2009). Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci. 30, 546-556.
45. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
46. Hartman, J. L. T., Garvik, B., and Hartwell, L. (2001). Principles for the buffering of genetic variation. Science 291, 1001-1004.
47. Hazlehurst, L. A., Argilagos, R. F., and Dalton, W. S. (2007). Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br. J. Haematol. 136, 269-275.
48. Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J., and Dalton, W. S. (2000). Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19, 4319-4327.
49. Hazlehurst, L. A., Enkemann, S. A., Beam, C. A., Argilagos, R. F., Painter, J., Shain, K. H., et al. (2003). Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 63, 7900-7906.
50. Hazlehurst, L. A., Valkov, N., Wisner, L., Storey, J. A., Boulware, D., Sullivan, D. M., et al. (2001). Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98, 1897-1903.
51. Heppner, G. H., Dexter, D. L., Denucci, T., Miller, F. R., and Calabresi, P. (1978). Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 38, 3758-3763.
52. Hipfner, D. R., Deeley, R. G., and Cole, S. P. (1999). Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461, 359-376.
53. Hofmann, W. K., Komor, M., Wassmann, B., Jones, L. C., Gschaidmeier, H., Hoelzer, D., et al. (2003). Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102, 659-661.
54. Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., et al. (2003). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432.
55. Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., et al. (2006). Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66, 7854-7858.
56. Ishikawa, T., and Ali-Osman, F. (1993). Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. 268, 20116-20125.
57. Isoyama, S., Dan, S., Nishimura, Y., Nakamura, N., Kajiwara, G., Seki, M., et al. (2012). Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance. Cancer Sci. 103, 1955-1960.
58. Jabbour, E., Kantarjian, H., Jones, D., Breeden, M., Garcia-Manero, G., O'Brien, S., et al. (2008). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112, 53-55.
59. Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M., Bekele, N., O'Brien, S., et al. (2006). Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20, 1767-1773.
60. Jedlitschky, G., Leier, I., Buchholz, U., Barnouin, K., Kurz, G., and Keppler, D. (1996). Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56, 988-994.
61. Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmana, J., et al. (2012). Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2, 1048-1063.
62. Kasahara, K., Fujiwara, Y., Nishio, K., Ohmori, T., Sugimoto, Y., Komiya, K., et al. (1991). Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 51, 3237-3242.
63. Kasper, M., and Toftgard, R. (2013). Smoothing out drug resistance. Cancer Cell 23, 3-5.
64. Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., and Lazo, J. S. (1988). Overexpression of metallothionein confers resistance to anticancer drugs. Science 241, 1813-1815.
65. Kelly, R. J., Draper, D., Chen, C. C., Robey, R. W., Figg, W. D., Piekarz, R. L., et al. (2011). A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Cancer Res. 17, 569-580.
66. Kobayashi, S., Boggon, T. J., Dayaram, T., Janne, P. A., Kocher, O., Meyerson, M., et al. (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792.
67. Konig, J., Nies, A. T., Cui, Y., Leier, I., and Keppler, D. (1999). Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461, 377-394.
68. Kreitman, R. J. (2006). Immunotoxins for targeted cancer therapy. AAPS J. 8, E532-E551.
69. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., Fitzgerald, D. J., et al. (2001). Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345, 241-247.
70. Krishnamurthy, P., Ross, D. D., Nakanishi, T., Bailey-Dell, K., Zhou, S., Mercer, K. E., et al. (2004). The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279, 24218-24225.
71. Kufe, D. W., and Spriggs, D. R. (1985). Biochemical and cellular pharmacology of cytosine arabinoside. Semin. Oncol. 12, 34-48.
72. Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., et al. (2011). Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 71, 5626-5634.
73. Kummar, S., Chen, A., Parchment, R. E., Kinders, R. J., Ji, J., Tomaszewski, J. E., et al. (2012). Advances in using PARP inhibitors to treat cancer. BMC Med. 10:25. doi: 10.1186/1741-7015-10-25
74. le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., et al. (2000). Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95, 1758-1766.
75. Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
76. Lichtenstein, A. V. (2005). On evolutionary origin of cancer. Cancer Cell Int. 5, 5.
77. Lippert, T. H., Ruoff, H. J., and Volm, M. (2011). Current status of methods to assess cancer drug resistance. Int. J. Med. Sci. 8, 245-253.
78. Longo-Sorbello, G. S., and Bertino, J. R. (2001). Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 86, 121-127.
79. Luo, J., Solimini, N. L., and Elledge, S. J. (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837.
80. Lwin, T., Hazlehurst, L. A., Dessureault, S., Lai, R., Bai, W., Sotomayor, E., et al. (2007). Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 110, 1631-1638.
81. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139.
82. Marusyk, A., and Polyak, K. (2010). Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805, 105-117.
83. Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., et al. (2003). Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9, 1158-1165.
84. Meads, M. B., Gatenby, R. A., and Dalton, W. S. (2009). Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665-674.
85. Meijer, C., Mulder, N. H., Timmer-Bosscha, H., Sluiter, W. J., Meersma, G. J., and De Vries, E. G. (1992). Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 52, 6885-6889.
86. Michor, F., and Polyak, K. (2010). The origins and implications of intratumor heterogeneity. Cancer Prev. Res. (Phila) 3, 1361-1364.
87. Monceviciute-Eringiene, E. (2005). Neoplastic growth: the consequence of evolutionary malignant resistance to chronic damage for survival of cells (review of a new theory of the origin of cancer). Med. Hypotheses 65, 595-604.
88. Montoni, A., Robu, M., Pouliot, E., and Shah, G. M. (2013). Resistance to PARP-inhibitors in Cancer Therapy. Front. Pharmacol. 4:18. doi: 10.3389/fphar.2013.00018
89. Mori, Y., Shimizu, N., Dallas, M., Niewolna, M., Story, B., Williams, P. J., et al. (2004). Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104, 2149-2154.
90. Mukherjee, S. (2010). The Emperor of All Maladies: a Biography of Cancer. New York: Scribner.
91. Negrini, S., Gorgoulis, V. G., and Halazonetis, T. D. (2010). Genomic instability - an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220-228.
92. Nesse, R. M. (2001). How is Darwinian medicine useful? West. J. Med. 174, 358-360.
93. Nguyen, L. V., Vanner, R., Dirks, P., and Eaves, C. J. (2012). Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12, 133-143.
94. Nicolini, F. E., Corm, S., Le, Q. H., Sorel, N., Hayette, S., Bories, D., et al. (2006). Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20, 1061-1066.
95. Nijman, S. M. (2011). Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 585, 1-6.
96. Nobili, S., Landini, I., Mazzei, T., and Mini, E. (2012). Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med. Res. Rev. 32, 1220-1262.
97. O'Brien, C. A., Pollett, A., Gallinger, S., and Dick, J. E. (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110.
98. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004.
99. O'Connor, D., Sibson, K., Caswell, M., Connor, P., Cummins, M., Mitchell, C., et al. (2011). Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 154, 482-485.
100. Palma, J. P., Rodriguez, L. E., Bontcheva-Diaz, V. D., Bouska, J. J., Bukofzer, G., Colon-Lopez, M., et al. (2008). The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer. Res. 28, 2625-2635.
101. Palma, J. P., Wang, Y. C., Rodriguez, L. E., Montgomery, D., Ellis, P. A., Bukofzer, G., et al. (2009). ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin. Cancer Res. 15, 7277-7290.
102. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73. doi: 10.1371/journal.pmed.0020073
103. Park, Y., and Gerson, S. L. (2005). DNA repair defects in stem cell function and aging. Annu. Rev. Med. 56, 495-508.
104. Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672.
105. Pinedo, H. M., and Giaccone, G. (1998). Drug Resistance in the Treatment of Cancer. Cambridge: Cambridge University Press.
106. Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., and Gottesman, M. M. (2012). Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15, 98-105.
107. Potten, C. S., Owen, G., and Booth, D. (2002). Intestinal stem cells protect their genome by selective segregation of template DNA strands. J. Cell Sci. 115, 2381-2388.
108. Raderer, M., and Scheithauer, W. (1995). Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. Eur. J. Cancer 31A, 1002-1008.
109. Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115.
110. Riffell, J. L., Lord, C. J., and Ashworth, A. (2012). Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 11, 923-936.
111. Sampath, D., Cortes, J., Estrov, Z., Du, M., Shi, Z., Andreeff, M., et al. (2006). Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107, 2517-2524.
112. Sawyers, C. (2004). Targeted cancer therapy. Nature 432, 294-297.
113. Schvimer, M., Lash, R. H., and Katzin, W. E. (1995). Intratumoral heterogeneity of DNA ploidy in breast carcinomas: a flow cytometric assessment of sampling techniques. Cytometry 22, 292-296.
114. Sellers, W. R. (2011). A blueprint for advancing genetics-based cancer therapy. Cell 147, 26-31.
115. Shain, K. H., Landowski, T. H., and Dalton, W. S. (2002). Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 168, 2544-2553.
116. Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L. A., et al. (2009). Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 69, 1009-1015.
117. Sharma, S. V., and Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231.
118. Shen, C. Y., Yu, J. C., Lo, Y. L., Kuo, C. H., Yue, C. T., Jou, Y. S., et al. (2000). Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 60, 3884-3892.
119. Shen, Z. (2011). Genomic instability and cancer: an introduction. J. Mol. Cell Biol. 3, 1-3.
120. Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132.
121. Siegel, R., Desantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241.
122. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792.
123. Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., et al. (2005). ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J. Clin. Oncol. 23, 4100-4109.
124. Stratton, M. R., Campbell, P. J., and Futreal, P. A. (2009). The cancer genome. Nature 458, 719-724.
125. Tallman, M. S., Nabhan, C., Feusner, J. H., and Rowe, J. M. (2002). Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99, 759-767.
126. Taron, M., Ichinose, Y., Rosell, R., Mok, T., Massuti, B., Zamora, L., et al. (2005). Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11, 5878-5885.
127. Teicher, B. A. (2006). Cancer Drug Resistance. Totowa: Humana Press.
128. Testi, A. M., Moleti, M. L., Giona, F., Iori, A. P., Meloni, G., Miniero, R., et al. (1992). Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children. Ann. Oncol. 3, 765-767.
129. The International Cancer Genome Consortium. (2010). International network of cancer genome projects. Nature 464, 993-998.
130. Thomas, D. A., Kantarjian, H., Smith, T. L., Koller, C., Cortes, J., O'Brien, S., et al. (1999). Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86, 1216-1230.
131. Toyooka, S., Kiura, K., and Mitsudomi, T. (2005). EGFR mutation and response of lung cancer to gefitinib. N. Engl. J. Med. 352, 2136; author reply 2136.
132. Trudeau, M. E., Crump, M., Charpentier, D., Yelle, L., Bordeleau, L., Matthews, S., et al. (2006). Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann. Oncol. 17, 952-956.
133. Tucker, C. L., and Fields, S. (2003). Lethal combinations. Nat. Genet. 35, 204-205.
134. Ullah, M. F. (2008). Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac. J. Cancer Prev. 9, 1-6.
135. Venezia, T. A., Merchant, A. A., Ramos, C. A., Whitehouse, N. L., Young, A. S., Shaw, C. A., et al. (2004). Molecular signatures of proliferation and quiescence in hematopoietic stem cells. PLoS Biol. 2:e301. doi: 10.1371/journal.pbio.0020301
136. Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., et al. (2007). Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin. Cancer Res. 13, 6469-6478.
137. Wang, S., Yang, D., and Lippman, M. E. (2003). Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin. Oncol. 30, 133-142.
138. Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., et al. (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245.
139. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297, 63-64.
140. Weinstein, I. B., and Joe, A. K. (2006). Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3, 448-457.
141. White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., et al. (2004). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6, 159-170.
142. Wild, P., Knuechel, R., Dietmaier, W., Hofstaedter, F., and Hartmann, A. (2000). Laser microdissection and microsatellite analyses of breast cancer reveal a high degree of tumor heterogeneity. Pathobiology 68, 180-190.
143. Williams, G. C., and Nesse, R. M. (1991). The dawn of Darwinian medicine. Q. Rev. Biol. 66, 1-22.
144. Wilson, T. R., Johnston, P. G., and Longley, D. B. (2009). Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets 9, 307-319.
145. Wilson, T. R., Longley, D. B., and Johnston, P. G. (2006). Chemoresistance in solid tumours. Ann. Oncol. 17(Suppl. 10), x315-x324.
146. Wong, A. L., and Lee, S. C. (2012). Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int. J. Breast Cancer 2012, 415170.
147. Xu, Y., and Villalona-Calero, M. A. (2002). Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. 13, 1841-1851.
148. Yauch, R. L., Dijkgraaf, G. J., Alicke, B., Januario, T., Ahn, C. P., Holcomb, T., et al. (2009). Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326, 572-574.
149. Zhang, P., Zuo, H., Ozaki, T., Nakagomi, N., and Kakudo, K. (2006). Cancer stem cell hypothesis in thyroid cancer. Pathol. Int. 56, 485-489.